Oint. T-Mycin
Ophthalmic Ointment · OPH · 0.3% / ophthalmic ointment · 3 gm
৳80
Oint., Soln.
T-Mycin
Tobramycin (Ophthalmic)
— Aristopharma Ltd.
0.3% / ophthalmic ointment · 0.3% / ophthalmic solution
Presentations
Soln. T-Mycin
Ophthalmic Solution · OPH · 0.3% / ophthalmic solution · 5 ml
৳100
Dose rules
No structured dose rules are linked to this brand yet.
Dose reference
Human
Ophthalmic ointment: In mild to moderate infection, apply a small amount 2-3 times daily into the conjunctival sac(s). In severe cases of infection, apply a small amount 3-4 times daily into the conjunctival sac(s) until improvement is obtained, then reduce the dose gradually. Ophthalmic solution: In mild to moderate infections: Instill 1or 2 drops into the affected eye(s) every 4 hours. In severe infections: Instill 2 drops into the affected eye(s) every hour until improvement is observed. Pediatric use: Safety and effectiveness in children below the age of 1 year have not been established.
Clinical notes
Applications:
N/A
Indication Notes:
Tobramycin is a topical antibiotic indicated in the treatment of external bacterial infections of the eye caused by susceptible organisms. Such as, Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus spp. of ... Read moreTobramycin is a topical antibiotic indicated in the treatment of external bacterial infections of the eye caused by susceptible organisms. Such as, Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus spp. of group A beta-hemolytic and some nonhemolytic species.Gram-negative bacteria: E.coli, Pseudomonas aeruginosa, Enterobacter aerogenes, Klebsiella spp., Proteusmirabillis, Proteus vulgaris, Haemophilus influenzae, Morganella morganii, Acinetobacter calcoaceticus, Providentia, Serratia, Salmonella spp and some strains of Neisseria.
Avoid In:
N/A
Contraindication Notes:
It is contraindicated in patients who are hypersensitive to Tobramycin or any of the ingredients of the preparation.
Like other aminoglycosides, the bactericidal activity of Tobramycin is taken up into sensitive bacterial cells by an active transport process. Within the cell Tobramycin bind to the 30s, and to some extent to the 50s subunits of the bacterial ribosome, inhibiting protein synthesis and generating errors in the transcription of the genetic code. The manner in which cell death is brought about is imperfectly understood, and other mechanisms may contribute, including effects on membrane permeability.
Care should be exercised when tobramycin is given to patients receiving other drugs with neuromauscular blocking agents or ototoxic.
The most frequent side effect of Tobramycin ophthalmic solution is localized ocular toxicity, conjunctival erythema, hypersensitivity including lid itching and swelling.
Sign and symptoms of overdose may be similar to side effects as described above.
Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should only be used during pregnancy, if the potential benefits outweigh the possible risk to the fetus. Drug may excreted into human milk. A decision should be made whether to discontinue nursing or to taking the drug.
Minor sensitivity may occur to topically applied aminoglycosides in some patients. If a sensitivity reaction occurs, discontinue use. Prolonged use may result in overgrowth of nonsusceptible organisms and fungi.